November 25, 2024
Alliance A092205: Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease
Overview: Alliance investigator Siddharth Sheth, DO, MPH, of UNC Lineberger Comprehensive Cancer Center, leads this phase III trial that compares the effect of adding cetuximab to pembrolizumab versus
David E. Kozono, MD, PhD, has been elected Group Vice-Chair of the Alliance for Clinical Trials in Oncology by the Alliance Board of Directors at the 2024 Alliance Fall Group Meeting. Dr. Kozono will take office on January 1, 2025. Dr. Kozono is an Associate Professor of Radiation Oncology at Harvard Medical School and Director of Thoracic Radiation Oncology at Dana-Farber/Brigham and Women’s Cancer Center. H
October 29, 2024
The Journal of the National Cancer Institute has published ‘Streamlining the Conduct of Cancer Clinical Trials: New Standard Data Collection Practices for National Cancer Institute Late Phase Clinical Studies,’ which assesses the impact of the stressors on
